An interventional study of electroacupuncture and Rehabilitation Training in Sarcopenia, sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University. Recruiting at 1 site in China. Open to participants aged 60 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by The Third Affiliated hospital of Zhejiang Chinese Medical University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 83 studies in Sarcopenia with a site in China — 47 open to participants now, 52 under way, 4 of them phase 3. Sarcopenia · China.
Among the 83 studies in Sarcopenia with a site in China, this one is the 21st largest by planned enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2022, is one of 42 with no phase, reaches primary completion later than 14 of the 51 other live ones, and was the 17th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →47 of the 83 studies in Sarcopenia with a site in China are open now. Recruiting first, the newest first:
Shanghai Yueyang Integrated Medicine Hospital · Sites in China
Ages 60–90
Hangzhou PhecdaMed Co., Ltd. · Sites in China
Ages 60+
GuangZhou Cellgenes Biotechnology Co., Ltd. · Sites in China
Ages 50–85
Peking Union Medical College Hospital · Sites in China
Ages 18+
China Medical University, China · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 60 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
83 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 3 · Phase 3 4 · Phase 4 3
First in 2012; this study’s year is marked. 5 started in 2022.
This study's planned enrollment of 120 is above the median of 60 across 860 interventional studies indexed under Sarcopenia.
Median enrollment 110 across the 52 interventional studies, 868 across the 31 observational. Of the 25 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 83 have an industry lead sponsor. The 10 most frequent:
The Third Affiliated hospital of Zhejiang Chinese Medical University is the lead sponsor of 45 studies on the registry; 25 are open to participants now.
The Third Affiliated hospital of Zhejiang Chinese Medical University has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
14 of the studies in Sarcopenia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07950150The Hong Kong Polytechnic UniversityPomegranate-Prebiotic Supplementation for Sarcopenic Obesity | 2026-12 |
| NCT07049731Weiwei MaImprovement of Skeletal and Muscle Health in Patients With Sarcopenia by Protein Powder With Resistance Exercise | 2026-12 |
| NCT07724587Ningbo Medical Center Lihuili HospitalThe Effectiveness and Safety of Combined Research on Uremic Sarcopenia | 2026-12-01 |
| NCT07059871Zhejiang HospitalA Study of Silkworm Pupa Powder Intervention in the Nutritional Status of Patients With Alzheimer's Disease. | 2026-12-30 |
| NCT07538674Shanghai Yueyang Integrated Medicine HospitalPeiyuan Guben Tongluo Ointment for Elderly Sarcopenia | 2027-03-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 83 studies in Sarcopenia with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Introduction: The efficacy of existing therapies for the treatment of sarcopenia is still not satisfactory. Therefore, this randomized controlled, assessor-blinded study was designed to investigate the efficacy and safety of electroacupuncture(EA) therapy in elderly patients with sarcopenia.
Methods and analysis: This randomized controlled trial will enroll 120 elderly patients with sarcopenia. Subjects will be randomly assigned in a 1:1 ratio to either EA combined with rehabilitation training group or rehabilitation training group through a central computerized randomization system. Primary outcome measure is lower limb mobility, including 6-minute walk test、timed get up and go test, and short physical performance battery. Secondary outcome measures include lower limb muscle mass and lower limb muscle strength. Outcome assessment will be conducted before the intervention, at 12 weeks after the intervention and at the end of the 12-week follow-up. Adverse reactions will be evaluated during the trial.
Conclusion: This research will provide evidence to clarify whether EA is effective and safe in the treatment of sarcopenia.
Introduction: The efficacy of existing therapies for the treatment of sarcopenia is still not satisfactory. Therefore, this randomized controlled, assessor-blinded study was designed to investigate the efficacy and safety of electroacupuncture(EA) therapy in elderly patients with sarcopenia.
Methods and analysis: This randomized controlled trial will enroll 120 elderly patients with sarcopenia. The experimental group is EA combined with rehabilitation training group, while the control group is rehabilitation training group. Rehabilitation training is the more recognized treatment method for sarcopenia all over the world. Eligible subjects will be randomly assigned to two group in a 1:1 allocation ratio. All participants will undergo 12 weeks of treatments in two groups. This protocol is based on the standards for Reporting Interventions in Clinical Trials of Acupuncture (STRICTA) and the SPIRIT reporting guidelines. Primary outcome measure is lower limb mobility, including 6-minute walk test、timed get up and go test, and short physical performance battery. Secondary outcome measures include lower limb muscle mass and lower limb muscle strength, such as lower extremity skeletal muscle mass、appendicular skeletal muscle mass、calf circumference、knee flexion and extension strength and grip strength. Outcome assessment will be conducted before the intervention, at 12 weeks after the intervention and at the end of the 12-week follow-up. Adverse reactions will be evaluated during the trial.
Conclusion: This research will provide evidence to clarify whether EA is effective and safe in the treatment of sarcopenia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will received electroacupuncture(EA) combined with Otago exercise program(OEP). Acupuncture will be executed with size 0.30×40mm needle. EA will be performed with electronic acupuncture instruments
Device: electroacupuncture · Behavioral: Rehabilitation Training
The rehabilitation group will be only treated with the Otago exercise program(OEP). The Otago Exercise is a program developed by the research group of fall prevention in the elderly led by Campbell of Otago Medical University in the 1990s. It is a home exercise program aimed at strengthening lower extremity muscle, balance and preventing falls in the elderly. Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia (details are as follows).
Behavioral: Rehabilitation Training
Participants are required to be in the supine position. Routine disinfection first. Participants are then subjected to acupuncture and achieve deqi sensation at all acupuncture points. Four paired of acupuncture points (i.e. Biguan acupoints and Futu points; Yanglingquan acupoints and Zusanli acupoints, identical on both sides) are connected to the EA devices. EA parameter is set as sparse wave and frequency is 2Hz. The intensity of the EA is determined by the patients' tolerance. Needles will be left in place and each session of EA will last 30 minutes. Participants will undergo a total of 36 EA sessions, with the frequency of 3 sessions every week for 12 weeks.
The rehabilitation training group will be only treated with the Otago exercise program(OEP). Otago Exercise combines resistance exercise, balance training and aerobic walking and is an exercise prescription for elderly patients with sarcopenia. 1. Exercise: including warm-up exercise (5 minutes) + resistance exercise (20 minutes) + balance training (5 minutes). Training intensity: 30 minutes a day, 3 times a week, once every other day, 12 weeks of training period; resistance exercise gradually increases the load. 2. Walking program: Take a walk. Activity intensity: 30 minutes each time, 2 times a week, combined with exercise (walking during the interval between exercise sessions), 12 weeks of training period
6min walk test
The 6-min walking test setup is a straight line of 20 meters on a flat floor, and a chair is placed at each end as a sign. The subjects walk back and forth between them. The pace of walking is determined according to their own physical fitness, and they walk as fast as possible. In this way, the maximum walking distance that an individual can reach within 6 minutes will be texted
Time frame: 12 weeks
time to get up and go(TGUG)
The TGUG test measures the time it takes for an individual to get up from a chair, complete a short 3 meters round-trip walk, and finally sit back in the chair.
Time frame: 12 weeks
short physical performance battery (SPPB)
SPPB is a comprehensive test instrument that includes a walking speed test, a sit-to-stand test, and a balance test. The Walking Speed Test measures the time to pass a distance of 4 meters at daily walking speed. Sit-to-stand test is to calculate the time to complete 5 consecutive sets of getting up-sit down. The balance test includes 3 parts: 10 seconds for standing on the left and right side of both feet; standing on half front and half rear feet and standing on front and rear feet
Time frame: 12 weeks
lower extremity skeletal muscle mass
The skeletal muscle mass of the lower limbs can be detected separately by applying the BCA body composition analyzer produced by Tsinghua Tongfang
Time frame: 12 weeks
appendicular skeletal muscle mass(ASMM)
The BCA body composition analyzer produced by Tsinghua Tongfang can be used to directly test the skeletal muscle mass of the extremities.
Time frame: 12 weeks
calf circumference
Measured by applying a measuring tape horizontally around the circumference of the thickest part of the calf
Time frame: 12 weeks
knee flexion and extension strength
The TB-ISO multi-joint isometric strength testing system (made in Italy) was applied to test the peak moment/peak moment body weight ratio, average power, and total work for the isometric exercise of knee flexion and knee extension, respectively.
Time frame: 12 weeks
grip strength
grip strength was obtained by grip strength measurement
Time frame: 12 weeks
Plan to share: No — no plan
Ran from Jul 2022 to primary completion in Dec 2025, 41 months.
Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 41 months is above that.
Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Third Affiliated hospital of Zhejiang Chinese Medical University